Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, on Thursday called out the need for better methodologies for identification and improvement of algorithms prone to mirroring "systemic biases" in the healthcare system and the data used to train artificial intelligence and machine learning-based devices, speaking at an FDA public workshop on the topic. The medical device industry should develop a strategy to enroll racially and ethnically diverse populations in clinical trials. "It's essential that the data used to train [these] devices represent the intended patient population with regards to age, gender, sex, race and ethnicity," Shuren said. The virtual workshop comes nine months after the agency released an action plan for establishing a regulatory approach to AI/ML-based Software as a Medical Device (SaMD). Among the five actions laid out in the plan, FDA intends to foster a patient-centered approach that includes device transparency for users.

Artificial intelligence in healthcare is the use of machine-learning algorithms and software to analyze, process and present complex medical and health care data. It has been widely used to support clinical decisions, improve workflows and predict health outcomes. Thus, wide application of AI in the healthcare sector is likely to propel the growth of the market. The growth of the artificial intelligence in healthcare market is attributed to the rising application of artificial intelligence in healthcare, growing investment in AI healthcare start-ups, and increasing cross-industry partnerships and collaborations. However, dearth of skilled AI workforce and imprecise regulatory guidelines for medical software is the major factor hindering the market growth.

Artificial intelligence tools in health care should be safe and effective. They should be fair to people of different races, genders, and geographies. And they should be monitored to ensure they are improving outcomes in the real world. Most participants agreed on those goals in a Food and Drug Administration workshop on the regulation of artificial intelligence late last week. But how to accomplish them remained a source of considerable debate.

Policymakers around the world are developing guidelines for use of artificial intelligence in health care. Baymax, the robotic health aide and unlikely hero from the movie Big Hero 6, is an adorable cartoon character, an outlandish vision of a high-tech future. But underlying Baymax's character is the very realistic concept of an artificial intelligence (AI) system that can be applied to health care. As AI technology advances, how will regulators encourage innovation while protecting patient safety? AI does not have a precise definition, but the term generally describes machines that have the capacity to process and respond to stimulation in a manner similar to human thought processes.

At the beginning of the year, I have a feeling that Graph Neural Nets (GNNs) became a buzzword. As a researcher in this field, I feel a little bit proud (at least not ashamed) to say that I work on this. It was not always the case: three years ago when I was talking to my peers, who got busy working on GANs and Transformers, the general impression that they got on me was that I was working on exotic niche problems. Well, the field has matured substantially and here I propose to have a look at the top applications of GNNs that we have recently had. If this in-depth educational content on graph neural networks is useful for you, you can subscribe to our AI research mailing list to be alerted when we release new material.

Artificial intelligence (AI) uses algorithms and software to perform certain tasks without human intervention and instructions. AI represents the integration of technologies such as machine learning, natural language processing, reasoning, and perception. It is used in healthcare for approximation of human cognition as well as the analysis of complex medical and diagnostic imaging data. The artificial intelligence in healthcare diagnosis market is driven by the ability of AI to provide improved outcomes; moreover, the growing need to increase coordination between healthcare workforce and patients also supports the market growth. The rise in the importance of Big Data in healthcare, increase in the adoption of precision medicine, and surge in venture capital investments also contribute to the market growth.

Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com. Last week's White House report reiterated President Biden's employer mandate that businesses with 100 or more employees require every worker to be fully vaccinated for COVID-19 or tested weekly. Jeffrey Zients, the White House COVID-19 response coordinator, summarized in last week's press briefing that, "We are on track to quadruple the supply of rapid, at-home tests available to Americans by December to more than 200 million a month and to increase the number of places Americans can access free testing in the United States to 30,000 community-based locations." He emphasized the president's staunch commitment in adding $1 billion of extra funding already to the recent $2 billion investment to increase supply.

READY FOR ITS CLOSE-UP: Artificial intelligence has long been hyped as a game changer in health care: Remember this 2012 prediction that computers will replace 80 percent of doctors? But it's been much harder to get a sense of the real-world scale of the phenomenon. Is AI a perpetual technology of the future? Or is it starting to get a toehold? A recently released Food and Drug Administration database starts to get at that question.

Preemptive recognition of the ethical implications of study design and algorithm choices in artificial intelligence (AI) research is an important but challenging process. AI applications have begun to transition from a promising future to clinical reality in neurology. As the clinical management of neurology is often concerned with discrete, often unpredictable, and highly consequential events linked to multimodal data streams over long timescales, forthcoming advances in AI have great potential to transform care for patients. However, critical ethical questions have been raised with implementation of the first AI applications in clinical practice. Clearly, AI will have far-reaching potential to promote, but also to endanger, ethical clinical practice. This article employs an anticipatory ethics approach to scrutinize how researchers in neurology can methodically identify ethical ramifications of design choices early in the research and development process, with a goal of preempting unintended consequences that may violate principles of ethical clinical care. First, we discuss the use of a systematic framework for researchers to identify ethical ramifications of various study design and algorithm choices. Second, using epilepsy as a paradigmatic example, anticipatory clinical scenarios that illustrate unintended ethical consequences are discussed, and failure points in each scenario evaluated. Third, we provide practical recommendations for understanding and addressing ethical ramifications early in methods development stages. Awareness of the ethical implications of study design and algorithm choices that may unintentionally enter AI is crucial to ensuring that incorporation of AI into neurology care leads to patient benefit rather than harm. AI= : artificial intelligence; ASM= : antiseizure medication; FDA= : Food and Drug Administration; RNS= : responsive neurostimulation

Artificial intelligence (AI) has undoubtedly been a growing presence in the healthcare industry, shaving years and billions of pounds off drug development programmes, accurately predicting A&E influxes, and even detecting early signs of disease in patients years before it was thought possible. The field of neuroscience has been no exception to this wave of technological innovation, with exciting developments cropping up in recent months and years that could potentially revolutionise diagnoses, treatments, and outcomes for patients on a global scale. The term AI covers a field of computer science that is focused upon the simulation of human intelligence and computational processes. However, there are several subfields of AI technology currently being explored in neuroscience, including machine learning (ML) and deep learning (DL). AI covers all programming systems that can perform tasks which usually require human intelligence.